Ophthalmology Doctors in Fairview Park, OH Accepting Medicare

5 Ophthalmology doctors found. Showing 1 - 5

Louis P Caravella, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 21375 Lorain Rd, Fairview Park, OH 44126 Phone: 440-333-7346    Fax: 440-333-0273

Carla M Krebs, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 21375 Lorain Rd, Fairview Park, OH 44126 Phone: 440-333-7346    Fax: 440-333-0273

Theodore Emmanuel Loizos, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 21375 Lorain Rd, Fairview Park, OH 44126 Phone: 440-333-7346    Fax: 440-333-0273

Alexander P Kosmidis, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 21375 Lorain Rd, Suite 203, Fairview Park, OH 44126 Phone: 440-333-3060    Fax: 440-333-0273

James R Conforto, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 21245 Lorain Rd, Ll100, Fairview Park, OH 44126 Phone: 440-331-6855    Fax: 440-331-9105

News Archive

War of sugars - estrogen provides protection in COVID-19

Now a new study published on the preprint server bioRxiv in July 2020 reports that sex hormones could affect the function of the fusion protein that is dependent upon the human ACE2 receptor, thus preventing the entry of the virus into the host cell.

USask's VIDO-Intervac receives $23 million to fast-track development of COVID-19 vaccine

The University of Saskatchewan's VIDO-InterVac (Vaccine and Infectious Disease Organization-International Vaccine Centre) has been awarded $23 million to fast-track efforts to develop a COVID-19 vaccine, Prime Minister Justin Trudeau announced today.

C-Path forms ePRO Consortium

Critical Path Institute has established the Electronic Patient-Reported Outcome (ePRO) Consortium comprising five member firms that provide innovative electronic data collection technologies for capturing patient-reported outcome (PRO) endpoints in clinical trials.

Emmaus reports preliminary top-line results from Phase 3 clinical trial for treatment of sickle cell disease

Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases, today announced that preliminary top-line results of its Phase 3 clinical trial evaluating the safety and efficacy of its treatment for sickle cell anemia and sickle beta-0 thalassemia met both the primary and secondary endpoints of the clinical trial.

Research roundup: Cutting speciality care by raising co-payments; Asthma diagnosis and insurance coverage; GAO on early retirees

Mayo Clinic Employees Responded To New Requirements For Cost Sharing By Reducing Possibly Unneeded Health Services Use - Researchers at the Mayo Clinic examined the effects of changes in the clinic's self-funded health plan "to decrease the use of potentially inappropriate health care services and foster a deliver system centered on primary care."

Read more Medical News

› Verified 2 days ago